Vivek Subbiah, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO20
6:47
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
Lung Cancer Similar Videos
-
Andreas N. Saltos, MD; Moffitt Cancer Center; 5Live; #IASLC21
13:27
-
Addressing Disparities in Cancer Care: Incorporating Precision Medicine for Minority Populations_Narjust Duma, MD_Nathaniel Evans III, MD
44:14
-
Strategies to optimize outcomes with targeted therapies in NSCLC_Blanca Ledezma, NP
15:46